Barrie Nicola, Manolios Nicholas
Department of Rheumatology, University of Sydney, Westmead Hospital, Sydney, Australia.
Eur J Rheumatol. 2017 Sep;4(3):210-218. doi: 10.5152/eurjrheum.2017.17025. Epub 2017 Sep 1.
Pain is the most common manifestation of both acute and chronic inflammation that often challenges patients with rheumatic disease. Simply, we attribute this to local joint changes of pH in joints, the formation of radicals, enhanced joint pressure, or cytokine release acting on local nerves to produce pain. However, there is a more complex interplay of interactions between cytokines, mediators of inflammation, and ion channels that influence the final immune response and our perception of pain. Endocannabinoids, a group of less well-known endogenous bioactive lipids, have such manifold immunomodulatory effects able to influence both inflammation and pain. In this review, we overview the endocannabinoid system, its role in pain, inflammation, and immune regulation, and highlight the emerging challenges and therapeutic hopes.
Eur J Rheumatol. 2017-9
Prostaglandins Leukot Essent Fatty Acids. 2002
Thromb Haemost. 2019-2-15
Adv Exp Med Biol. 2018
Curr Neuropharmacol. 2018-1-30
Int J Mol Sci. 2019-11-23
Gut Microbiome (Camb). 2025-2-14
ACS Chem Biol. 2025-4-18
Molecules. 2024-10-17
Int J Mol Sci. 2024-8-29
Int Clin Psychopharmacol. 2025-7-1
Autoimmun Rev. 2016-2-11
Trends Pharmacol Sci. 2015-5
Immunology. 2015-3
BMC Musculoskelet Disord. 2014-8-12